EFFECTIVE TREATMENT FOR PRIMARY LOCALLY AGGRESSIVE INTERMEDIATE AND MALIGNANT SOFT TISSUE TUMOURS OF THE BREAST

OBJECTIVE  This study aimed to examine the rare locally aggressive intermediate tumours and malignant primary breast mesenchymal tumours in the patients receiving surgical treatment. SUMMARY OF BACKGROUND DATA  Locally aggressive intermediate tumours were subdivided into non-metastasising and rarely metastasising, while malignant group was subdivided as a single subgroup called able to metastasise. A retrospective examination of surgical notes and clinical charts was carried out reviewing gender, age, symptoms, duration of symptoms, tumour size, clinical presentation, radiation history, kind of surgery undergone, adjuvant radiotherapy, adjuvant chemotherapy, local recurrences, systemic metastases and mortality. RESULTS  Mitotic index and Ki-67 were statistically different between locally aggressive and malignant groups (p ˂ 0.001). One local recurrence occurred in only one patient diagnosed as dermatofibrosarcoma protuberans among all patients. None of the entities showed distant metastasis or mortality. In this result, clear margin of surgery in locally aggressive intermediate group and combination of surgery with radiation therapy in the malignant group was the most important determinant for the prospect of the patients with mean follow up 28 months. CONCLUSION  The main treatment for localised mesenchymal breast tumours is surgery. When the disease is locally advanced or malignant with high mitotic index, radiotherapy with surgery is predominantly used.Targeted therapies are promising with the limited place of chemotherapy.